Health Canada is aware of recent concerns around the use of mannitol as a non-medicinal ingredient in medications for use by pregnant women. Health Canada would like to reassure Canadians that, based on its evaluation of the evidence available to date, consumption of small quantities of sugar substitutes, including mannitol, during pregnancy does not pose a health risk.
Mannitol is a type of sugar commonly used as a non-medicinal ingredient in medications, such as tablets or capsules, to help in the manufacture of the product. Non-medicinal ingredients are evaluated for safety. They are used, for example, to help hold a tablet together or give it colour.
Mannitol has a long history of safe consumption in many products commonly used and consumed by pregnant women, including folic acid supplements, vitamins, candy and baked goods. Mannitol also occurs naturally in many foods, including cauliflower, mushrooms, snow peas, and peaches.
Foreign Product Alerts: Weight loss products
October 27, 2017
These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients. Body Con Plus capsules, Physic Candy, Define, 7-day slim extreme capsules.
The products are not authorized for sale in Canada and have not been found in the Canadian marketplace, but it is possible they may have been brought into the country by travellers or purchased over the Internet.
Advisory: Unauthorized Sexual Enhancement Products Seized
Nov 1, 2017
Health Canada is advising Canadians that multiple unauthorized sexual enhancement products seized from four Toronto retail locations may pose serious risks to health.
Stop using these products. Consult with your health care professional if you have used any of these products and have health concerns.
Read product labels to verify that health products have been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada’s Drug Product Database and Licensed Natural Health Product Database.
Drug Recall: Sertraline
September 11, 2017
Health Canada is advising of a recall of Setraline 50mg, as it may contain capsules of Sertraline 25mg.
Drug Recall: pms-Bisadocyl
September 15, 2017
Health Canada is advising of a recall of pms-Bisacodyl due to results not meeting specifications for the stability of the active ingredient content.
Advisory: Thermograms are not a substitute for mammograms
Sep 28, 2017
Health Canada is reminding Canadians and women in particular, that thermograms (which use thermal imaging) are not a substitute for mammograms used for routine monitoring and screening for breast cancer. While thermography devices are available in Canada, these devices have not been licensed in Canada to screen for breast cancer. They have been licensed by Health Canada only to measure skin temperature, similar to a thermometer.
Health Canada is not aware of any clinical evidence that thermography devices can be used effectively for the early detection of breast cancer. If women are relying solely on thermography results, there is a potential risk that cancer could go undetected.
Mammography, which is a low-dose x-ray system to see inside the breasts, is the most reliable technique in screening for early-stage breast cancer, and has been proven to be safe and effective. Specialized equipment used in mammography is licensed by Health Canada and is widely available across Canada.
Recall of Cannabis for Medical Purposes
August 24, 2017
On August 24, 2017, Broken Coast Cannabis Ltd., a licensed producer of cannabis for medical purposes located in British Columbia, has begun a voluntary Type III recall of 3 lots of dried marijuana that were produced between June to July 2016. The affected lot numbers are found below.
Following the inspection at the Broken Coast Cannabis Ltd. site in March 2017 to conduct random sampling of cannabis products, a test result for a cannabis oil sample in July 2017 showed the presence of myclobutanil and spinosad, at levels below quantifiable limits.
This resulted in further sampling of cannabis products from the licensed producer site where a cannabis leaf sample indicated the presence of myclobutanil at a level of 0.017 parts per million (ppm). The licensed producer undertook further testing of their products through a third party laboratory, which indicated the presence of myclobutanil. As a result, Broken Coast Cannabis Ltd. is recalling three lots of dried marijuana sold between July and December 2016.
Health Canada is advising consumers that the unauthorized prescription product “Kobayashi Eyebon Eyewash” may pose serious health risks. The product is labelled to contain the prescription drug, aminocaproic acid, and is promoted as an eyewash for contact lens users and for the prevention of eye disease. The product, sold in three formats (Cool, Mild and Regular), was seized at the Catwalk Boutique retail location in Burnaby, B.C. (1313 – 4500 Kingsway). The product was also being sold online (www.ac-beauty.com/shop) and at the Catwalk Boutique retail location in Richmond, B.C. (2005 - 4000 No.3 Rd.).
The unauthorized health product was packaged and labelled in Japanese. As a result, information about ingredients, usage, dosage and side effects may not be understood by all consumers. Products that contain prescription drug ingredients should only be taken under the supervision of a health professional because they are used to treat specific diseases, and may cause serious side effects.
Recall: Apotex recalls a lot of Nitroglycerin
Sep 1st, 2017
Health Canada is advising Canadians that Apotex Inc. is voluntarily recalling one lot (lot 6G07) of its Apo-Nitroglycerin sublingual (under the tongue) spray (0.4 mg/metered dose) as the spray pump may malfunction and not deliver the drug.
Nitroglycerin is a prescription drug used to relieve acute attacks of angina (chest pain). The pump is intended to deliver the drug by spraying it under the tongue. Patients experiencing angina who do not receive nitroglycerin could be at risk of suffering a heart attack.
Drug Recall: Bayer recalls RestoraLAX due to choking hazards
July 8, 2017
Further to a recent recall of RestoraLAX 45+10, Health Canada is advising Canadians that Bayer Inc. is expanding its voluntary recall to include specific lots of RestoraLAX 30+7 Bonus Packs sold at various retailers across Canada due to a potential choking hazard. Specific lots of RestoraLAX 30+7 Bonus Packs may contain deposits such as clumps or lumps. The presence of these deposits may pose a choking hazard. RestoraLAX is used to relieve occasional constipation and irregularity.